

1 **Title:** Global Menstrual Cycle Symptomatology as Reported by Users of a Menstrual Tracking
2 Mobile Application

3 Alessandra J Ainsworth, MD ¹

4 Kimberly Peven, PhD²

5 Ryan Bamford, MSc²

6 Liudmila Zhaunova, PhD²

7 Rodion Salimgaraev, MD²

8 Carley Prentice, BA²

9 Aidan Wickham, PhD²

10 Adam Cunningham, PhD²

11 Frederick Goddard, PhD²

12 Sonia Ponzio, PhD^{2,3}

13 Samir N Babayev, MD ¹

14
15 ¹ Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and
16 Infertility, Mayo Clinic, Rochester, Minnesota

17 ² Flo Health UK Limited, London, United Kingdom

18 ³ University College London, Institute of Health Informatics

19
20 Address Correspondence to: Samir N. Babayev, MD

21 Mayo Clinic

22 200 First Street SW

23 Rochester, MN 55905

24 (507) 284-9792

25 Babayev.samir@mayo.edu

26

27 **Abstract**

28 Background: Although a shared experience throughout the world, menstrual symptomatology is
29 underreported and often misunderstood, by both individuals who menstruate and their providers.

30 This study aimed to investigate symptomatology throughout the menstrual cycle, including the
31 frequency of symptoms reported for each phase of the cycle and the relationship between
32 symptoms.

33 Methods: This study included self-reported cycle information and symptoms during ovulatory
34 menstrual cycles in mobile application users. Symptom frequency was described overall, by
35 phase, and by day. Relationships between symptoms were examined through correlation
36 coefficients and term frequency-inverse document frequency analysis.

37 Results: 437,577 unique users and 896,051 unique cycles were included in the analysis. Somatic
38 symptoms were most frequently reported, logged in 88.3% of cycles. Of the total symptoms
39 logged, somatic, gastrointestinal, and negative mood symptoms were most prevalent in the late
40 luteal and bleeding days. In contrast, positive mood and discharge were most reported in the
41 fertile window. Mood symptoms were highly correlated with each other (energetic mood and
42 happy mood $r=0.62$, anxious mood and obsessive thoughts $r=0.60$). Fatigue was highly
43 correlated with somatic and gastrointestinal symptoms such as bloating ($r=0.62$), headache
44 ($r=0.60$), backache ($r=0.58$), and nausea ($r=0.55$).

45 Conclusions: Menstrual cycle-related symptoms are very common and vary throughout the
46 menstrual cycle. While negative symptoms, including pain, bloating, and negative mood, are

47 most commonly reported, women also report positive symptoms, such as energetic and happy
48 mood. Self-reported data from cycle tracking and health apps can improve our understanding of
49 the prevalence and variability of menstrual-related symptoms.

50

51 **Trial Registration:** Not applicable.

52

53 **Key Words:** Menstrual symptoms, Menstruation, Period Tracking, Mobile Application

54

55 **Plain English Summary:** Our study includes data collected from users of a menstrual tracking
56 application. We found that menstrual symptoms are common, throughout the menstrual cycle,
57 and include both positive and negative mood and physical symptoms. This large data set may
58 help to normalize menstrual symptoms and provide a basis for future research and understanding.

59 **Background:**

60 Although a shared experience by women and people who menstruate throughout the
61 world, menstruation represents an area of health often ignored and misunderstood by both
62 patients and healthcare providers. While many individuals experience menstruation without
63 significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood
64 symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating
65 individuals, with wide variation due to differing definitions of the condition (1). Compared with
66 pain-free phases of their cycles, those suffering from dysmenorrhea experience reduced quality
67 of life, poor mood, and decreased sleep during menstruation (1). Gastrointestinal symptoms also
68 vary throughout the menstrual cycle, with one-third of women experiencing symptoms during
69 menstruation (2), most frequently on the first day of bleeding (3).

70 Additionally, irritability and mood swings can affect 22-40% of women, more often
71 before menstruation (4). As it relates to symptom co-occurrence, individuals with mood
72 symptoms like depression and anxiety are more likely to experience multiple gastrointestinal
73 symptoms both before and during menstruation (5). Despite improved standardization in
74 terminology and increasing prioritization of women’s health issues, these symptoms are under
75 reported (6–8). Importantly, menstrual symptoms may present a significant impairment to
76 productivity and quality of life (9).

77 A recent review highlighted challenges in the field of menstrual health research (10).
78 These challenges include how and from whom data is collected, normalization of symptoms,
79 stigma regarding menstrual disorders, lack of standardized assessment tools, and differing
80 cultural perceptions of this physiologic process (10–13). Previous studies of symptom prevalence
81 and variation throughout the menstrual cycle are small prospective or survey studies (4,5). Given
82 these limitations, there remain gaps in our knowledge of patient symptoms and opportunities for
83 further study.

84 The emerging availability of mobile applications (apps) and user-reported data provides
85 a novel approach to population health, in this instance, menstrual symptomatology, through
86 ‘digital epidemiology’ (14–16). The impact of digital epidemiology to inform our understanding
87 of population norms in menstrual health recently demonstrated a luteal phase length of 12.4 ± 2
88 days (17). These results differ from the classical teaching of a conserved 14-day luteal phase
89 (17).

90 In this study, through in-app user-reported data, we aim to report a population-based
91 assessment of symptomatology throughout the menstrual cycle. Specific objectives include

92 describing the frequency of symptoms reported in each phase of the menstrual cycle and analysis
93 of the relationship between symptoms.

94 **Methods:**

95 This cohort study includes active users of the Flo app recording symptoms during an ovulatory
96 cycle starting between January 1, 2021, and January 1, 2023. Users aged 18-45, not pregnant,
97 and actively involved in the app (reporting at least three menstrual cycles) were included.
98 Menstrual cycles between 21-35 days, menstrual bleeding between 1-10 days, follicular and
99 luteal phase lengths of at least five days each, positive ovulation predictor kit use, and at least
100 one self-reported menstrual symptom at any point in the cycle were included as ‘normal’
101 menstrual cycles.

102 Cycle dates and phases were calculated based on user-provided data. Users report the
103 start and end dates of their period and the date of positive ovulation test. Each cycle start date is
104 defined as the first day of bleeding. The mid-follicular phase was defined as the day after the last
105 day of menstrual bleeding until the start of the fertile window (Figure 1). An individual with less
106 than five days between the end of menstrual bleeding and the day of ovulation had no defined
107 mid-follicular phase. The fertile window was calculated as the five days preceding ovulation and
108 the day of ovulation was estimated as the day following a user-reported positive ovulation
109 predictor kit. The luteal phase was split evenly in half and described as the early luteal phase and
110 the late luteal phase.

111 Symptoms were self-reported and associated with the phase of the menstrual cycle as
112 defined above. We classified symptoms into five groups: somatic (cramps, tender breasts,
113 headache, fatigue, backache, acne), gastrointestinal (GI) (bloating, nausea, diarrhea, cravings,

114 constipation), positive mood (happy, high sex drive, energetic), negative mood (mood swings,
115 anxious, depressed, insomnia, stress, obsessive thoughts), and discharge (creamy, eggwhite,
116 sticky, watery). Users could record as many symptoms in each category as desired each day.

117 Individual characteristics were matched to each cycle. Age at the time of the cycle was
118 based on the user's birthdate and cycle dates. A user's country was assigned based on phone
119 settings at app installation. Where the country at app installation was unavailable, country phone
120 settings at the last login was used. Country prevalence of symptoms was evaluated only when
121 100 users or more were included.

122 **Statistical Methods**

123 Using a cycle-level unit of analysis, we employed descriptive statistics to describe cycle
124 length and symptoms experienced overall and by phase. For cycles with a length of 25-30 days,
125 we describe symptoms experienced by day of the cycle, where day 1 is the first day of bleeding.
126 We examined the correlation between all possible pairs of symptoms using a cycle-level unit of
127 analysis considering symptoms experienced at any point in the cycle. We reported Pearson
128 correlation coefficients for each possible pair. We also conducted a term frequency-inverse
129 document frequency (tf-idf) analysis (18) for pairs of symptoms separately by cycle phase to
130 describe the frequency of pairs of any symptoms, taking into account the frequency of the
131 individual symptoms that make up the pair. This is calculated as term frequency times inverse
132 document frequency, where term frequency is defined as the number of instances of a pair of
133 symptoms in a cycle phase, and inverse document frequency is defined as the logarithm of the
134 number of users logging one symptom from the pair during the relevant cycle phase divided by
135 the total number of symptoms logged in the phase. Data were analyzed in Python Jupyter
136 Notebook 6.0.1 and R version 4.2.0.

137 **Results:**

138 A total of 437,577 unique users and 896,051 unique, normal menstrual cycles met
139 inclusion criteria with an average of 2.05 ± 1.8 cycles per user (Figure 2). The mean age of users
140 was 30.0 ± 5.4 years; users under age 18 or over 45 were excluded from the analysis. Users were
141 included from 222 countries, with 113 countries having at least 100 users. The largest group of
142 users was in the United States ($n=126,352$), followed by Germany ($n=45,018$) and the United
143 Kingdom ($n=35,007$).

144 Of the 437,577 unique users included in this analysis (last cycle), the mean cycle length
145 was 28.4 ± 2.6 days (median 28.0 days), and the mean length of bleeding was 4.0 ± 1.1 days
146 (median 4.0 days). Most included cycles had a length of 25-31 days (75.7%, $n=331,360$),
147 followed by a length of ≥ 32 days (15.8%, $n=69,479$) and <25 days (8.4 %, $n=36,738$).
148 Calculated from the predicted day of ovulation, the mean follicular phase length amongst users
149 was 14.4 ± 3.0 days (median 14.0 days), and the mean luteal phase length was 14.0 ± 2.7 days
150 (median 14.0 days).

151 Of the 896,051 unique cycles, somatic symptoms were reported most often; 88.3%
152 ($n=790,923$) of cycles reported at least one somatic symptom. Comparatively, gastrointestinal
153 symptoms and discharge symptoms were reported in 60.8% of cycles each ($n=545,107$ and
154 $544,460$, respectively), negative mood symptoms were reported in 43.3% ($n=388,249$) of cycles,
155 and positive mood symptoms were reported in 35.4% ($n=317,558$). The type and frequency of
156 symptoms are shown in Figure 3. Menstrual cramps, breast tenderness, headache, and fatigue
157 were the most common symptoms reported.

158 Symptoms were next assessed by the menstrual cycle phase. Somatic, gastrointestinal,
159 and negative mood symptoms were most frequent in the late luteal phase and least frequent in the

160 mid-follicular phase (Figure 4). 57.3% of all logged instances of tender breasts occurred during
161 the late luteal phase compared to 1.8% in the mid-follicular phase. Discharge and positive mood
162 symptoms were most common during the fertile window. 63.1% of all logged instances of egg
163 white discharge and 45.3% of all logged instances of high sex drive were during the fertile
164 window.

165 For cycles between 25-30 days in length (n=570,123 cycles), we examined daily
166 symptom logs for the three symptoms with the most variability per category (Figure 5). Overall,
167 most symptoms are reported on day 1 of the cycle (436,812 symptoms logged from 211,021
168 cycles out of 570,123 total cycles); however, the fertile window is where most cycles have at
169 least one symptom logged. Out of 570,123 total cycles, 382,115 cycles had at least one symptom
170 logged during the fertile window, and 283,652 had at least one symptom logged during the
171 bleeding days. The prevalence of somatic, gastrointestinal, and negative mood symptoms are
172 highest on day 1 but decline quickly, reaching their lowest point around day 7 before slowly
173 increasing throughout the rest of the cycle. For positive mood symptoms, the prevalence of
174 energetic mood remains relatively stable throughout the cycle. In contrast, happy and high-sex-
175 drive moods increase slowly in the early part of the cycle, peaking around day 14 of the cycle
176 and reaching baseline around day 20. Discharge symptoms are rarely logged during the early part
177 of the cycle where bleeding occurs. Egg white discharge increases rapidly between days 6 and 13
178 before decreasing quickly to a low level by day 20.

179 For countries with at least 100 users, the number per country ranged from 103 in The
180 Bahamas to 126,352 in the United States (Supplemental Table 1). The prevalence of cramps
181 during the last cycle ranged from 30.5% in Vietnam to 74.6% in Iceland (Figure 6). Bloating

182 ranged from 17.6 in Thailand to 49.7% in Chile. Mood swings ranged from 13.3% in Hong Kong
183 to 43.1% in Iraq.

184 Mood symptoms were most highly correlated with each other. The anxious mood was
185 highly correlated with obsessive thoughts ($r=0.60$) and depressed mood ($r=0.58$). Depressed
186 mood was correlated with obsessive thoughts ($r=0.55$), and happy mood was highly correlated
187 with energetic mood ($r=0.62$, Figure 7). Similarly, fatigue was highly correlated with somatic
188 and gastrointestinal symptoms such as bloating ($r=0.62$), headache ($r=0.60$), backache ($r=0.58$),
189 and nausea ($r=0.55$).

190 A term frequency-inverse document frequency (tf-idf) analysis by cycle phase showed
191 how pairs of symptoms correlate within cycle phases, adjusting for the frequency of individual
192 symptoms (Figure 8 and Supplementary Tables 2 and 3). During the bleeding days and late luteal
193 phase when cramps are common, the top five tf-idf values all included cramps, and cramps were
194 most closely associated with nausea (tf-idf = 54,861 bleeding days, tf-idf = 68,467 late luteal).
195 Happy and energetic were the top pair in the mid-follicular phase (tf-idf=23,333) and second in
196 the fertile window (tf-idf=55,636).

197 Discussion:

198 In this study, we report the frequency of somatic, gastrointestinal, mood, and discharge
199 symptoms experienced throughout the menstrual cycle by a cohort of global, ovulating period-
200 tracking app users. Notably, most users were aged 30-34 and located in Europe and the United
201 States. Our results build on prior work evaluating the menstrual cycle characteristics of women
202 using period-tracking apps. The median cycle length, 28.8 days in our study, is consistent with
203 previous studies and period tracking app data (17,19–22).

204 Somatic symptoms were reported most frequently, with cramps being the most reported
205 symptom. Somatic, gastrointestinal, and negative mood symptoms were more common in the
206 late luteal phase than in the rest of the cycle. They reached a nadir in the mid-follicular phase
207 between bleeding and the fertile window/ovulation. The hormonal changes observed in the luteal
208 phase may explain these findings. There is a direct correlation between the rapid rise of
209 progesterone, the dominant sex hormone in the luteal phase, and the abrupt increase in somatic
210 symptoms. Progesterone has been shown to influence breast changes and associated breast
211 tenderness in the luteal phase (23). By thermoregulatory actions, progesterone has also been
212 shown to impact circadian rhythms leading to decreased rapid eye movement (REM) sleep in the
213 luteal phase and, thus a reported increase in fatigue (24). However, progesterone levels fall in the
214 week prior to menstruation while somatic symptoms continue to increase. Symptoms in the late
215 luteal phase reflect the effect of decreasing systemic sex steroid hormones. Pain disorders, such
216 as migraines and non-migraine headaches, have been shown to increase in the late luteal phase
217 when estradiol levels are lowest (25–27), in line with our findings of headaches being most
218 reported in this phase. These effects are modulated by estrogen effects on central pain processing
219 networks and cerebral vasculature (26). Conversely, decreasing progesterone levels and the
220 resultant increase in available androgen receptors may explain the increase in acne reported in
221 the late luteal phase (28).

222 Gastrointestinal symptoms that increase throughout the luteal phase likely reflect multiple
223 mechanisms (3). First, the effect of progesterone on serotonergic activity in both the central
224 nervous system and the GI tract slows gastrointestinal motility leading to constipation in the
225 early luteal phase (29). Second, increasing prostaglandin levels in the late luteal phase lead to

226 stimulation of smooth muscle contractions – leading to both uterine cramping and increased
227 gastrointestinal motility and associated diarrhea (30).

228 The effect of the menstrual cycle on mental health has been well studied, and
229 premenstrual mood disorders are well classified, with over 300 subtypes reported. Mood changes
230 in the luteal phase affect 50-80% of reproductive-aged women, although 3-8% of individuals
231 have such severe symptoms with associated functional impairments that they meet diagnostic
232 criteria in the DSM-V (31). Our study confirmed an increase in negative mood symptoms
233 throughout the luteal phase, possibly reflecting known alterations in sex steroids and the
234 following neurotransmitters: serotonin, noradrenaline, and gamma-aminobutyric acid (GABA)
235 (31,32). Negative mood symptoms decreased throughout the follicular phase, with a
236 corresponding increase in positive mood symptoms that reached peak levels in the late follicular
237 phase. Positive mood symptom frequency in the follicular phase is consistent with prior studies
238 reporting individual well-being to be highest at this time in the cycle (33,34). Recent work
239 utilizing functional magnetic resonance imaging (fMRI) has added to our understanding. Sex
240 hormones appear to impact communication between brain regions, in addition to their known
241 impact on neurotransmitter secretion (35). This impacts cognition and emotional processing,
242 such that estrogen seems to decrease reaction to negative stimuli while progesterone seems to
243 increase emotional reactions to negative stimuli (36).

244 The relationship between mood and somatic symptoms during the menstrual cycle has
245 been evaluated with mixed results. One study found an increase in mood symptoms in women
246 with gastrointestinal symptoms, skin changes, breast changes, and abdominal bloating. At the
247 same time, there was no effect of concurrent mood symptoms seen in women who reported back
248 and joint pain (37). We found negative mood symptoms (depressed mood, mood swings, anxious

249 mood) co-occurred with cramps in the bleeding days and late luteal phase while positive mood
250 symptoms (energetic and happy) occurred together in the mid-follicular through early luteal
251 phases, without strong associations with somatic symptoms.

252 We found small geographic differences in user-reported symptoms during the menstrual
253 cycle. This may reflect the impact of knowledge or sociocultural constructs, which impact
254 individual perceptions of symptoms and their menstrual experience (38). Historically,
255 menstruation has been described negatively. Previous work has shown an association between
256 early menstrual/menarchal experiences and current menstrual experience, body perception, and
257 overall health (39–42). However, other studies examining symptom experience across broad
258 geographic regions have not found regional differences in symptoms (43).

259 The strength of this study lies in the number of unique users and in the large amount of
260 user-reported data from a global population. However, this study is not without limitations.
261 Specifically, this study is subject to selection bias as not all menstruating individuals choose to
262 use period-tracking apps. Demographic and other individual characteristic data were not
263 collected, including user-reported race and ethnicity, which may be important mediators of
264 menstrual symptom characteristics and experiences that may impact our results. We included
265 only ovulatory cycles where ovulation was confirmed by self-ovulation test to more accurately
266 divide the cycle into phases. Users logging ovulation tests likely have a goal of conception and
267 may thus have a different experience of menstrual symptoms and a difference in the tendency of
268 logging symptoms. Additionally, irregular and non-ovulatory cycles are not represented in this
269 analysis, and results are not generalizable to these populations. Although this study represents a
270 global menstruating population, many countries remain absent or underrepresented, presenting
271 an opportunity for future research. Other limitations include the use of self-reported symptom-

272 tracking data. Users log symptoms through the app but may not log symptoms consistently
273 throughout the cycle (e.g., potentially more likely to log symptoms when logging other events
274 such as ovulation or period) and may not log all symptoms experienced. Users also may be more
275 likely to log symptoms that appear at the top and front of the app over symptoms that appear
276 lower down or require scrolling to see. This decreases the representativeness of symptoms
277 recorded and limits our ability to compare results with other methods of symptom data
278 collection.

279 **Conclusions:**

280 Our study presents an expanded understanding of symptoms experienced during the
281 menstrual cycle. These findings reflect the value of population-level menstrual cycle data, which
282 can help inform individual patients and clinicians while strengthening research efforts and calls
283 for advocacy for Women’s Health.

284
285 **Abbreviations:**

286 GI: gastrointestinal

287 Tf-idf: term frequency-inverse document frequency

288 REM: rapid eye movement

289 DSM-V: Diagnostic and Statistical Manual of Mental Disorders, 5th edition

290 GABA: gamma-aminobutyric acid

291 fMRI: functional magnetic resonance imaging

292

293 **Declarations:**

- 294 1. IRB approval waived. Documentation attached as supporting document
- 295 2. Consent for publication: Not applicable
- 296 3. Availability of data and materials: The datasets used and/or analyzed during the current
- 297 study are available from the corresponding author on reasonable request.
- 298 4. Competing interests:
- 299 KP: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
- 300 RB: Flo Health UK Limited (Employment)
- 301 LZ: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
- 302 RS: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
- 303 CP: Flo Health UK Limited (Employment)
- 304 AW: Flo Health UK Limited (Employment, ownership interest, stock/stock options)
- 305 AC: Flo Health UK Limited (Employment)
- 306 FG: Flo Health UK Limited (Employment)
- 307 SP: Flo Health UK Limited (Employment, ownership interest, stock/stock options).
- 308 Other authors did not report any potential conflicts of interest.
- 309 5. Author contributions:
- 310 AJA: Design, interpretation of data, drafted and substantially revised work
- 311 KP: Design; acquisition, analysis, and interpretation of data; drafted and substantially
- 312 revised work


- 313 RB: Acquisition, analysis, and interpretation of data
- 314 LZ: Design, interpretation of data, and substantively revised work
- 315 RS: Design; acquisition, analysis, and interpretation of data
- 316 CP: Analysis and interpretation of data
- 317 AW: Acquisition, analysis, and interpretation of data
- 318 AC: Acquisition, analysis, and interpretation of data
- 319 FG: Analysis and interpretation of data
- 320 SP: Interpretation of data and substantively revised work
- 321 SB: Design, interpretation of data, substantially revised work
- 322 6. Acknowledgements: None


323 **References**

3241. Lacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical
325 review. *Hum Reprod Update*. 2015 Nov 1;21(6):762–78.
3262. Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual
327 cycle? *Br J Obstet Gynaecol*. 1998 Dec;105(12):1322–5.
3283. Judkins TC, Dennis-Wall JC, Sims SM, Colee J, Langkamp-Henken B. Stool frequency and
329 form and gastrointestinal symptoms differ by day of the menstrual cycle in healthy adult women
330 taking oral contraceptives: a prospective observational study. *BMC Womens Health*. 2020 Jun
331 29;20(1):136.
3324. Lete I, Häusler G, Pintiaux A, Jamin C, Nappi RE, Fiala C, et al. The inconvenience due to
333 women’s monthly bleeding (ISY) survey: a study of premenstrual symptoms among 5728
334 women in Europe. *Eur J Contracept Reprod Health Care Off J Eur Soc Contracept*. 2017
335 Oct;22(5):354–9.
3365. Bernstein MT, Graff LA, Avery L, Palatnick C, Parnerowski K, Targownik LE. Gastrointestinal
337 symptoms before and during menses in healthy women. *BMC Womens Health*. 2014 Jan
338 22;14:14.
3396. Chen CX, Draucker CB, Carpenter JS. What women say about their dysmenorrhea: a qualitative
340 thematic analysis. *BMC Womens Health*. 2018 Mar 2;18(1):47.
3417. Chen CX, Kwekkeboom KL, Ward SE. Beliefs About Dysmenorrhea and Their Relationship to
342 Self-Management. *Res Nurs Health*. 2016 Aug;39(4):263–76.
3438. Ramos-Pichardo JD, Ortega-Galán ÁM, Iglesias-López MT, Abreu-Sánchez A, Fernández-
344 Martínez E. Why Do Some Spanish Nursing Students with Menstrual Pain Fail to Consult
345 Healthcare Professionals? *Int J Environ Res Public Health*. 2020 Nov 5;17(21):E8173.

3469. Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE. Productivity loss
347 due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748
348 women. *BMJ Open*. 2019 Jun 27;9(6):e026186.
34910. Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, et al.
350 Menstruation: science and society. *Am J Obstet Gynecol*. 2020 Nov;223(5):624–64.
35111. Matteson KA, Zaluski KM. Menstrual Health as a Part of Preventive Health Care. *Obstet*
352 *Gynecol Clin North Am*. 2019 Sep;46(3):441–53.
35312. Chen CX, Shieh C, Draucker CB, Carpenter JS. Reasons women do not seek health care for
354 dysmenorrhea. *J Clin Nurs*. 2018 Jan;27(1–2):e301–8.
35513. Tan DA, Haththotuwa R, Fraser IS. Cultural aspects and mythologies surrounding menstruation
356 and abnormal uterine bleeding. *Best Pract Res Clin Obstet Gynaecol*. 2017 Apr;40:121–33.
35714. Symul L, Wac K, Hillard P, Salathé M. Assessment of menstrual health status and evolution
358 through mobile apps for fertility awareness. *NPJ Digit Med*. 2019;2:64.
35915. Mao L, Xi S, Bai W, Yao C, Zhou Y, Chen X, et al. Menstrual patterns and disorders among
360 Chinese women of reproductive age: A cross-sectional study based on mobile application data.
361 *Medicine (Baltimore)*. 2021 Apr 23;100(16):e25329.
36216. Karasneh RA, Al-Azzam SI, Alzoubi KH, Muflih SM, Hawamdeh SS. Smartphone Applications
363 for Period Tracking: Rating and Behavioral Change among Women Users. *Obstet Gynecol Int*.
364 2020;2020:2192387.
36517. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-world
366 menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med*.
367 2019;2:83.
36818. Leskovec J, Rajaraman A, Ullman JD. *Mining of Massive Data Sets*. Cambridge University
369 Press; 2020. 566 p.
37019. Li K, Urteaga I, Wiggins CH, Druet A, Shea A, Vitzthum VJ, et al. Characterizing physiological
371 and symptomatic variation in menstrual cycles using self-tracked mobile-health data. *NPJ Digit*
372 *Med*. 2020;3:79.
37320. Najmabadi S, Schliep KC, Simonsen SE, Porucznik CA, Egger MJ, Stanford JB. Menstrual
374 bleeding, cycle length, and follicular and luteal phase lengths in women without known
375 subfertility: A pooled analysis of three cohorts. *Paediatr Perinat Epidemiol*. 2020
376 May;34(3):318–27.
37721. Li K, Urteaga I, Shea A, Vitzthum VJ, Wiggins CH, Elhadad N. A predictive model for next
378 cycle start date that accounts for adherence in menstrual self-tracking. *J Am Med Inform Assoc*
379 *JAMIA*. 2021 Dec 28;29(1):3–11.
38022. Broad A, Biswakarma R, Harper JC. A survey of women’s experiences of using period tracker
381 applications: Attitudes, ovulation prediction and how the accuracy of the app in predicting period
382 start dates affects their feelings and behaviours. *Womens Health Lond Engl*. 2022
383 Dec;18:17455057221095246.
38423. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. *Endocr Rev*. 1997
385 Aug;18(4):502–19.
38624. Shechter A, Varin F, Boivin DB. Circadian variation of sleep during the follicular and luteal
387 phases of the menstrual cycle. *Sleep*. 2010 May;33(5):647–56.
38825. LeResche L, Mancl L, Sherman JJ, Gandara B, Dworkin SF. Changes in temporomandibular
389 pain and other symptoms across the menstrual cycle. *Pain*. 2003 Dec;106(3):253–61.
39026. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their
391 impact on vascular diseases. *J Headache Pain*. 2012 Apr;13(3):177–89.

39227. Stening K, Eriksson O, Wahren L, Berg G, Hammar M, Blomqvist A. Pain sensations to the cold
393 pressor test in normally menstruating women: comparison with men and relation to menstrual
394 phase and serum sex steroid levels. *Am J Physiol Regul Integr Comp Physiol*. 2007
395 Oct;293(4):R1711-1716.
39628. Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. *Clin Exp*
397 *Dermatol*. 2015 Mar;40(2):111–5.
39829. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation of G-
399 protein levels in female chronic constipation. *Gastroenterology*. 2005 Mar;128(3):667–75.
40030. Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. *Rev Endocr Metab*
401 *Disord*. 2012 Dec;13(4):277–88.
40231. Ryu A, Kim TH. Premenstrual syndrome: A mini review. *Maturitas*. 2015 Dec;82(4):436–40.
40332. Toffol E, Kalleinen N, Urrila AS, Himanen SL, Porkka-Heiskanen T, Partonen T, et al. The
404 relationship between mood and sleep in different female reproductive states. *BMC Psychiatry*.
405 2014 Jun 16;14:177.
40633. Sanders D, Warner P, Bäckström T, Bancroft J. Mood, sexuality, hormones and the menstrual
407 cycle. I. Changes in mood and physical state: description of subjects and method. *Psychosom*
408 *Med*. 1983 Dec;45(6):487–501.
40934. Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated with the
410 menstrual cycle in a community-based sample in the Midwestern United States. *Psychiatry Res*.
411 2005 Mar 30;134(1):27–36.
41235. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional and
413 cognitive functional imaging of estrogen and progesterone effects in the female human brain: a
414 systematic review. *Psychoneuroendocrinology*. 2014 Dec;50:28–52.
41536. Sakaki M, Mather M. How reward and emotional stimuli induce different reactions across the
416 menstrual cycle. *Soc Personal Psychol Compass*. 2012 Jan 1;6(1):1–17.
41737. Kiesner J, Pastore M. Day-to-day co-variations of psychological and physical symptoms of the
418 menstrual cycle: insights to individual differences in steroid reactivity.
419 *Psychoneuroendocrinology*. 2010 Apr;35(3):350–63.
42038. Marván ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about
421 premenstrual syndrome. *Psychosom Med*. 1999 Apr;61(2):163–7.
42239. McPherson ME, Korfine L. Menstruation across time: menarche, menstrual attitudes,
423 experiences, and behaviors. *Womens Health Issues Off Publ Jacobs Inst Womens Health*. 2004
424 Dec;14(6):193–200.
42540. Stubbs ML. Cultural perceptions and practices around menarche and adolescent menstruation in
426 the United States. *Ann N Y Acad Sci*. 2008;1135:58–66.
42741. Padmanabhanunni A, Jaffer L, Steenkamp J. Menstruation experiences of South African women
428 belonging to the ama-Xhosa ethnic group. *Cult Health Sex*. 2018 Jun;20(6):704–14.
42942. Barrington DJ, Robinson HJ, Wilson E, Hennegan J. Experiences of menstruation in high
430 income countries: A systematic review, qualitative evidence synthesis and comparison to low-
431 and middle-income countries. *PloS One*. 2021;16(7):e0255001.
- 432 43. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of
433 premenstrual symptoms with age and sociodemographic factors. *Menopause Int*. 2011
434 Sep;17(3):96–101.





Follicular phase

day one:
cycle start

time from the last day of
menstruation to the first day
of the fertile window

ovulation:
day following
last
self-reported
ovulation test
date

bleeding days

mid-follicular

fertile window

ov.

early luteal

late luteal

self-reported
menstrual days


the five-day window
preceding ovulation

first half of the luteal phase


cycle end

Luteal phase


second half of the luteal
phase




Bleeding days




Mid follicular




Fertile window




Early luteal




Late luteal




Cramps




Bloating




Mood swings



Prevalence



| | Acne | Anxious | Backache | Bloating | Constipation | Cramps | Cravings | Creamy Discharge | Depressed | Diarrhea | Eggwhite Discharge | Energetic | Fatigue | Happy | Headache | High Sex Drive | Insomnia | Mood Swings | Nausea | Obsessive Thoughts | Sticky Discharge | Stress | Tender Breasts | Watery Discharge |
|--------------------|------|---------|----------|----------|--------------|--------|----------|------------------|-----------|----------|--------------------|-----------|---------|-------|----------|----------------|----------|-------------|--------|--------------------|------------------|--------|----------------|------------------|
| Acne | | | | | | | | | | | | | | | | | | | | | | | | |
| Anxious | 0.35 | | | | | | | | | | | | | | | | | | | | | | | |
| Backache | 0.41 | 0.35 | | | | | | | | | | | | | | | | | | | | | | |
| Bloating | 0.45 | 0.39 | 0.51 | | | | | | | | | | | | | | | | | | | | | |
| Constipation | 0.34 | 0.29 | 0.38 | 0.48 | | | | | | | | | | | | | | | | | | | | |
| Cramps | 0.35 | 0.29 | 0.5 | 0.49 | 0.33 | | | | | | | | | | | | | | | | | | | |
| Cravings | 0.38 | 0.34 | 0.39 | 0.48 | 0.35 | 0.33 | | | | | | | | | | | | | | | | | | |
| Creamy Discharge | 0.33 | 0.26 | 0.34 | 0.38 | 0.27 | 0.38 | 0.27 | | | | | | | | | | | | | | | | | |
| Depressed | 0.31 | 0.58 | 0.31 | 0.32 | 0.26 | 0.25 | 0.3 | 0.21 | | | | | | | | | | | | | | | | |
| Diarrhea | 0.27 | 0.24 | 0.32 | 0.35 | 0.24 | 0.32 | 0.26 | 0.23 | 0.2 | | | | | | | | | | | | | | | |
| Eggwhite Discharge | 0.25 | 0.2 | 0.27 | 0.29 | 0.22 | 0.31 | 0.21 | 0.4 | 0.16 | 0.18 | | | | | | | | | | | | | | |
| Energetic | 0.26 | 0.27 | 0.23 | 0.28 | 0.2 | 0.21 | 0.27 | 0.3 | 0.19 | 0.18 | 0.24 | | | | | | | | | | | | | |
| Fatigue | 0.48 | 0.45 | 0.58 | 0.62 | 0.43 | 0.49 | 0.48 | 0.4 | 0.37 | 0.37 | 0.31 | 0.29 | | | | | | | | | | | | |
| Happy | 0.3 | 0.29 | 0.28 | 0.32 | 0.22 | 0.27 | 0.27 | 0.39 | 0.18 | 0.21 | 0.28 | 0.62 | 0.37 | | | | | | | | | | | |
| Headache | 0.44 | 0.37 | 0.54 | 0.49 | 0.36 | 0.49 | 0.38 | 0.35 | 0.33 | 0.32 | 0.28 | 0.25 | 0.6 | 0.31 | | | | | | | | | | |
| High Sex Drive | 0.24 | 0.23 | 0.27 | 0.27 | 0.21 | 0.25 | 0.29 | 0.27 | 0.2 | 0.18 | 0.23 | 0.3 | 0.3 | 0.32 | 0.27 | | | | | | | | | |
| Insomnia | 0.32 | 0.34 | 0.36 | 0.4 | 0.36 | 0.3 | 0.38 | 0.24 | 0.31 | 0.27 | 0.19 | 0.2 | 0.46 | 0.2 | 0.37 | 0.21 | | | | | | | | |
| Mood Swings | 0.4 | 0.46 | 0.42 | 0.44 | 0.32 | 0.36 | 0.42 | 0.34 | 0.44 | 0.26 | 0.26 | 0.3 | 0.5 | 0.31 | 0.44 | 0.31 | 0.35 | | | | | | | |
| Nausea | 0.33 | 0.3 | 0.47 | 0.46 | 0.34 | 0.47 | 0.35 | 0.29 | 0.27 | 0.33 | 0.23 | 0.18 | 0.55 | 0.22 | 0.5 | 0.25 | 0.33 | 0.36 | | | | | | |
| Obsessive Thoughts | 0.29 | 0.6 | 0.3 | 0.32 | 0.26 | 0.22 | 0.33 | 0.2 | 0.55 | 0.19 | 0.16 | 0.22 | 0.36 | 0.21 | 0.3 | 0.2 | 0.3 | 0.42 | 0.25 | | | | | |
| Sticky Discharge | 0.29 | 0.24 | 0.28 | 0.32 | 0.23 | 0.3 | 0.24 | 0.43 | 0.19 | 0.19 | 0.33 | 0.26 | 0.34 | 0.33 | 0.3 | 0.23 | 0.21 | 0.29 | 0.23 | 0.19 | | | | |
| Stress | 0.29 | 0.47 | 0.28 | 0.28 | 0.22 | 0.2 | 0.27 | 0.2 | 0.4 | 0.19 | 0.15 | 0.19 | 0.34 | 0.2 | 0.3 | 0.19 | 0.27 | 0.38 | 0.2 | 0.43 | 0.19 | | | |
| Tender Breasts | 0.32 | 0.22 | 0.39 | 0.4 | 0.28 | 0.46 | 0.3 | 0.33 | 0.19 | 0.23 | 0.27 | 0.2 | 0.42 | 0.23 | 0.39 | 0.22 | 0.25 | 0.31 | 0.38 | 0.17 | 0.26 | 0.15 | | |
| Watery Discharge | 0.25 | 0.22 | 0.29 | 0.31 | 0.23 | 0.31 | 0.23 | 0.37 | 0.17 | 0.21 | 0.33 | 0.23 | 0.32 | 0.28 | 0.29 | 0.22 | 0.2 | 0.27 | 0.26 | 0.17 | 0.27 | 0.16 | 0.26 | |



Percentage of symptom occurrence during each phase

